cldn7b Antibody

What is Claudin-7 and why is it significant in biological research?

Claudin-7 (CLDN7) is a crucial tight junction protein that plays essential roles in maintaining epithelial barrier integrity and regulating ion homeostasis, particularly Cl- and Na+ permeability across epithelial barriers . CLDN7 has garnered significant research interest due to its dysregulation in various cancers. It is significantly overexpressed in breast cancer, with this overexpression correlating with poor disease-free survival (DFS) . Similarly, CLDN7 elevation has been observed across all major subtypes of ovarian cancer including serous, endometrioid, clear cell, and mucinous variants . Its involvement in both physiological barrier function and pathological processes makes it a valuable target for antibody-based research approaches.

What types of CLDN7 antibodies are currently available for research applications?

Research laboratories have access to diverse CLDN7 antibodies with varying specifications:

The selection should be guided by specific experimental requirements, including target species, application methods, and the specific epitope of interest .

How do I select between polyclonal and monoclonal CLDN7 antibodies for my research?

The selection depends on specific research objectives:

Monoclonal antibodies target a single epitope, providing superior specificity and consistency between batches. This consistency is particularly valuable for longitudinal studies or when comparing results across different experimental timepoints .

For novel applications where CLDN7 detection may be challenging, beginning with polyclonal antibodies may provide better likelihood of detection. For standardized assays requiring reproducibility and precise epitope targeting (such as phosphorylation-specific detection), monoclonal antibodies often represent the better choice.

What are the optimized protocols for immunohistochemical detection of CLDN7 in tissue samples?

For reliable immunohistochemical detection of CLDN7, researchers have successfully employed the EnVision method with the following protocol:

• Use primary anti-CLDN7 antibody (e.g., Abcam, ab207300) at a dilution of 1:200

• Apply appropriate HRP-conjugated secondary antibodies (matched to primary antibody host species)

• Visualize antibody binding using DAB dye solution

• Assess CLDN7 expression using a semi-quantitative scoring system:

  • Staining intensity: 3 (strong), 2 (moderate), 1 (weak), 0 (no expression)

  • Proportion of positive cells: 3 (51-100%), 2 (11-50%), 1 (1-10%), 0 (no staining)

Properly processed samples will typically show CLDN7 localization in cytoplasmic and/or cytomembrane regions, appearing as brown-yellow staining in positive samples . This standardized approach facilitates comparative analysis across different tissue specimens and experimental conditions.

What are the recommended antibody dilutions and conditions for different experimental applications?

Optimal antibody working concentrations vary by application method:

These dilutions serve as starting points, and optimization through dilution series is recommended for specific experimental conditions, tissue types, and detection systems . Antibody effectiveness can be influenced by sample preparation, fixation methods, and incubation conditions.

How can I rigorously validate the specificity of a CLDN7 antibody?

Comprehensive validation requires multiple complementary approaches:

• Genetic controls: Compare staining between wild-type (CLDN7+/+) and CLDN7 knockout (CLDN7-/-) samples, as demonstrated in collecting duct (CD) cell studies where antibody signals were present in wild-type but absent in knockout cells .

• Expression knockdown: Utilize RNA interference approaches (shRNA/siRNA) targeting CLDN7, then confirm reduced antibody signal. Studies have successfully employed this approach to validate antibody specificity and establish experimental models for functional studies .

• Multi-method validation: Confirm findings using different detection techniques (e.g., immunofluorescence microscopy, western blotting, and RT-PCR) to ensure consistent results across methodologies .

• Antibody cross-validation: Compare results using multiple antibodies targeting different CLDN7 epitopes to confirm consistent localization and expression patterns.

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding sites, which should eliminate specific staining.

What are the critical storage and handling conditions to maintain CLDN7 antibody performance?

To preserve antibody functionality:

• Store concentrated stock at -20°C in the buffer provided (typically PBS with 0.05% sodium azide and 50% glycerol, pH 7.4)

• Avoid repeated freeze-thaw cycles by preparing single-use aliquots

• For working solutions, store at 4°C for short periods (1-2 weeks)

• Follow manufacturer-specific recommendations, as formulations may vary

• Check for precipitates before use and centrifuge if necessary

• Use aseptic techniques when handling antibody solutions to prevent contamination

How can CLDN7 antibodies be utilized to investigate tight junction dynamics and ion transport?

CLDN7 antibodies enable sophisticated analyses of junction biology:

• Localization studies: Immunofluorescence can reveal CLDN7 distribution at cell-cell contacts to assess junction integrity. In functional tight junctions, CLDN7 typically shows strong membrane localization at intercellular borders .

• Structure-function analysis: Correlate CLDN7 expression patterns with transepithelial electrical resistance (TER) measurements and ion permeability. Research has demonstrated that CLDN7 deficiency increases TER while decreasing Cl- and Na+ permeability, indicating its role in regulating paracellular ion transport .

• Protein interaction networks: Use CLDN7 antibodies for co-immunoprecipitation to identify binding partners that modulate tight junction assembly and function.

• Phosphorylation dynamics: Employ phospho-specific antibodies (such as anti-pTyr210) to investigate post-translational modifications that regulate CLDN7 activity and localization .

• Rescue experiments: After CLDN7 knockdown, reintroduction of the protein can restore wild-type phenotypes, confirming functional relationships. Studies have demonstrated that CLDN7 re-expression in knockdown cells normalizes TER values and ion permeability .

What approaches should be used when investigating CLDN7 expression in cancer tissues?

When studying CLDN7 in cancer contexts:

• Expression quantification: Implement semi-quantitative scoring systems that assess both staining intensity and proportion of positive cells to accurately characterize CLDN7 expression levels .

• Clinicopathological correlations: Analyze relationships between CLDN7 expression and clinical parameters such as tumor stage, grade, and patient survival. In breast cancer, CLDN7 overexpression has been associated with poor disease-free survival .

• Immune microenvironment assessment: Investigate connections between CLDN7 expression and immune cell infiltration. Research indicates CLDN7 overexpression negatively correlates with B-cells, CD4+ T-cells, and CD8+ T-cells but positively with M0 macrophages in breast cancer tissues .

• Pathway analysis: Examine how CLDN7 dysregulation influences key signaling networks. Studies have shown CLDN7-related immune factors predominantly affect NF-κB and T-cell receptor signaling pathways in breast cancer .

• Differential expression analysis: Compare CLDN7 expression across cancer subtypes. Research demonstrates CLDN7 elevation across diverse ovarian cancer subtypes including serous, endometrioid, clear cell, and mucinous variants .

How can CLDN7 antibodies be employed for mechanistic studies of ion homeostasis?

For investigating CLDN7's role in ion regulation:

• Expression correlation studies: Use antibodies to analyze relationships between CLDN7 and ion transport regulators. Research has shown that CLDN7 deletion increases expression of WNK4, SGK-1, and all ENaC subunits in collecting duct cells, suggesting regulatory connections .

• Functional rescue approaches: Re-express CLDN7 in knockout or knockdown models to determine if wild-type ion permeability characteristics can be restored, confirming direct regulatory relationships .

• Localization and trafficking analysis: Investigate how CLDN7 expression affects membrane localization of ion channels. Studies have observed that AQP2 membrane localization is reduced in CLDN7-deficient cells despite similar total protein levels .

• Biophysical measurement correlations: Link CLDN7 expression to measurements of dilution potential and ion permeability to establish structure-function relationships .

• Phosphorylation state analysis: Investigate how post-translational modifications of CLDN7 affect ion channel regulation using phospho-specific antibodies .

What technical considerations apply when using phospho-specific CLDN7 antibodies?

When employing phosphorylation-specific antibodies:

• Signal validation: Include dephosphorylation controls (samples treated with phosphatase) to confirm signal specificity.

• Preservation of modifications: Use phosphatase inhibitors during sample preparation to prevent loss of phosphorylation.

• Context-dependent phosphorylation: Consider that CLDN7 phosphorylation may vary with cell type, stimulation conditions, and disease state.

• Temporal dynamics: Design time-course experiments to capture transient phosphorylation events following cellular stimulation.

• Pathway integration: Combine phospho-specific antibody analysis with kinase inhibitor treatments to identify regulatory pathways controlling CLDN7 phosphorylation.

What factors influence CLDN7 localization patterns and how should variations be interpreted?

CLDN7 localization can vary based on multiple factors:

How can heterogeneous or unexpected CLDN7 expression patterns be verified?

When encountering unexpected results:

• Multi-antibody verification: Employ antibodies targeting different CLDN7 epitopes to confirm observations.

• Complementary detection methods: Supplement immunohistochemistry with other techniques like western blotting or RT-PCR to verify expression levels .

• Single-cell analysis: Consider that heterogeneous expression may reflect biological variability rather than technical issues. Flow cytometry or single-cell immunofluorescence can characterize population heterogeneity.

• mRNA-protein correlation: Compare protein detection with mRNA expression analysis to identify discrepancies that might indicate post-transcriptional regulation.

• Functional correlation: Link expression patterns to functional readouts such as barrier measurements or ion permeability to establish biological relevance .

What are common technical issues with CLDN7 antibodies in Western blotting and how can they be resolved?

Troubleshooting Western blot detection:

• Multiple bands: CLDN7 can exhibit post-translational modifications or protein-protein interactions that alter migration. Compare observed band patterns with predicted molecular weight (~22-27 kDa) and include knockout controls .

• Weak signal: Optimize protein extraction from membrane fractions using appropriate detergents. For tight junction proteins, avoid harsh extraction conditions that may denature epitopes.

• High background: Increase blocking stringency (5% milk or BSA) and optimize antibody dilutions (1:1000-1:3000 for most applications) .

• Transfer issues: Claudins are small proteins that can be challenging to transfer efficiently. Use smaller pore-size PVDF membranes and optimize transfer conditions (time, voltage, buffer composition).

• Sample preparation: Include protease and phosphatase inhibitors during extraction to prevent degradation and preserve post-translational modifications.

What controls are essential for rigorous CLDN7 antibody-based experiments?

Comprehensive experimental design requires:

• Genetic controls: Include CLDN7 knockout or knockdown samples as negative controls .

• Loading and transfer controls: Employ housekeeping proteins for Western blots to normalize expression data.

• Technical controls:

  • Omit primary antibody while retaining secondary antibody to detect non-specific binding

  • Include isotype controls using irrelevant antibodies of the same isotype

  • For tissue staining, include known positive and negative tissues

• Functional validation: Perform rescue experiments where CLDN7 is reintroduced into knockout cells to confirm phenotype reversal and antibody specificity .

• Processing controls: For phosphorylation studies, include phosphatase-treated samples to confirm specific recognition of the phosphorylated form.